Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010–December 2018. Issue 6 (5th February 2020)

• Record Type: Journal Article
• Authors: Haber, Penina; Moro, Pedro L.; Ng, Carmen; Dores, Graça M.; Perez-Vilar, Silvia; Marquez, Paige L.; Cano, Maria
• Is Part Of: Vaccine. Volume 38:Issue 6(2020)
• Page Start: 1476
• Page End: 1480
• Publication Date: 2020-02-05
• Subjects: Vaccine safety -- Post-licensure surveillance -- Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) -- Vaccine Adverse Event Reporting System; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.11.074
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Introduction: The Advisory Committee on Immunization Practices (ACIP) recommends vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in persons ≥65 years of age. To date, few studies have assessed the safety of Tdap in this population. We aimed to summarize reports submitted to the Vaccine Adverse Event Reporting System (VAERS) following receipt of Tdap in this age group. Methods: We searched for and analyzed U.S. VAERS reports of Tdap among individuals ≥65 years of age submitted from September 1, 2010 through December 31, 2018. We classified reports according to concurrent vaccination, seriousness, and outcome (death, non-death) and determined the frequency of reported adverse events (AEs). For serious reports, we reviewed available medical records. Data mining analyses were undertaken to detect disproportionality in reporting. Results: VAERS received a total of 1, 798 reports following Tdap, of which 104 (6%) were serious. The most common AEs were injection site erythema (26%; n = 468), injection site pain (19%; n = 335), injection site swelling (18%; n = 329), and erythema (18%; n = 321). We identified seven deaths; none were attributed to Tdap. Among serious non-death reports, nervous system disorders (35.1%; n = 34) and infections and infestations (n = 18.6%; n = 18) were most commonly reported. Data mining did not identify any vaccine-AE combination reported more frequently than expected. Conclusions: We did not identify any new safety concern over nearly a decade of recommended Tdap use among adults ≥65 years of age. Findings from this post-marketing review are consistent with prior post-marketing observations and pre-licensure studies.